A Phase 1 Clinical Trial of NTQ5082 in Healthy Volunteers

Phase 1 Not yet recruiting 82 enrolled Nanjing Chia-tai Tianqing Pharmaceutical

RandomizedParallel-groupDouble-blindTreatment

Summary

NTQ5082 capsule is a small molecule CFB factor inhibitor. The study is a randomized, double-blind, placebo-controlled, dose escalation phase 1 clinical trial to evaluate the safety, tolerability and PK/PD characteristics of NTQ5082 capsules orally administered in healthy subjects in single and multiple doses.

Timeline

Start: 2024-08
Primary completion: 2024-12
Completion: 2025-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NTQ5082	Small molecule	—	Oral

Indications

No indication recorded.